AGP Executive Report

Visa Policy Pressure: 11 EU countries are urging the European Commission to tighten visa rules for Russian citizens, citing rising tourist and multiple-entry permits amid the war in Ukraine, with France, Italy and Spain taking the biggest share. Local Charity & Health Support: Two men are cycling the EuroVelo 15 Rhine route through Switzerland, Liechtenstein, Austria, Germany, France and the Netherlands to raise funds for a bereavement suite for baby-loss families at Southmead Hospital. Cancer Care Update: The European Commission approved Bristol Myers Squibb’s Opdivo (nivolumab) plus AVD as the first immunotherapy-based regimen in the EU for newly diagnosed advanced classical Hodgkin lymphoma in adults and adolescents (12+). Travel Health Access: UK travel guidance highlights that missing a GHIC card can mean higher out-of-pocket costs for state healthcare abroad, so travellers should apply before departure (GHIC doesn’t replace travel insurance). Pet Health Tech: Fi expanded its AI-powered GPS pet wearables and connectivity to 38 countries, including coverage for Switzerland, Norway and Liechtenstein. Drug Approval: CinnaGen became the first Iranian pharma firm to get EU approval for its osteoporosis medicine Zandoriah (teriparatide).

Visa Policy & Public Health Travel Risk: 11 EU countries are urging the European Commission to tighten visa rules for Russian citizens, citing rising tourist permits and fears that loopholes let more visitors reach Europe despite the war in Ukraine. Local Charity & Bereavement Care: Two men are cycling along the Rhine route through Switzerland, Liechtenstein, Austria, Germany, France and the Netherlands to raise funds for a dedicated baby-loss bereavement suite at Southmead Hospital. Cancer Treatment Access: The European Commission approved Bristol Myers Squibb’s Opdivo (nivolumab) plus AVD as the first immunotherapy-based regimen in the EU for newly diagnosed advanced classical Hodgkin lymphoma in adults and adolescents (12+). Pet Health Tech in the Region: Fi expanded AI-powered GPS pet wearables and connectivity to 38 countries, including coverage for Switzerland and Liechtenstein, aiming to help owners track health and behavior while traveling. Travel Costs & Healthcare Coverage: UK guidance highlights that travellers without a GHIC may miss state-provided medical treatment abroad, urging people to apply before travel (and still keep travel insurance). Medication Innovation: CinnaGen received EU approval for its osteoporosis drug teriparatide (Zandoriah), marking a first for an Iranian pharma company.

Charity Cycling for Baby Loss in Liechtenstein Region: Two men will ride the EuroVelo 15 Rhine Cycle Route from June 12, camping across Switzerland, Liechtenstein, Austria, Germany, France and the Netherlands to raise funds for Freddie’s Yellow Rose, aiming to build a dedicated bereavement suite at Southmead Hospital. EU Drug Approvals: CinnaGen became the first Iranian pharma firm to win European Commission approval for its osteoporosis medicine Zandoriah (teriparatide). Cancer Care in Europe: The European Commission approved Bristol Myers Squibb’s Opdivo (nivolumab) plus AVD as the first immunotherapy-based regimen in the EU for newly diagnosed advanced classical Hodgkin lymphoma in adults and adolescents (12+). Pet Health Tech in the Region: Fi expanded its AI-powered GPS pet wearables to 38 countries, including coverage for Switzerland, Norway and Liechtenstein, with behavior insights aimed at spotting health changes. Heat and Health Risks: A Europe-wide spring heat wave has shattered temperature records and is linked to multiple deaths, with warnings that more may follow. Local Sports Leadership (Liechtenstein connection): FIS president Johan Eliasch defended commercial-rights centralisation ahead of a June 11 re-election vote, with Liechtenstein’s Alexander Ospelt among candidates.

EU Drug Approvals: CinnaGen became the first Iranian pharma to win European Commission approval for its osteoporosis medicine Zandoriah (teriparatide), following EMA CHMP positive opinions and strict EU GMP checks. Cancer Care in Europe: The European Commission also approved Bristol Myers Squibb’s Opdivo (nivolumab) plus AVD as the first immunotherapy-based regimen in the EU for newly diagnosed advanced classical Hodgkin lymphoma in patients aged 12+. Health Tech in the Region: Fi expanded its AI-powered GPS pet wearables to 38 countries, adding coverage across parts of North America and Europe and including Switzerland, Norway, and Liechtenstein. Heat & Safety: A deadly spring heat wave across Europe has shattered temperature records and is linked to multiple deaths, with warnings that more incidents may follow. Travel Health Access (UK): UK guidance highlights that travellers should apply for a free GHIC card before trips to help access state healthcare abroad, but it doesn’t replace travel insurance. Local Relevance: For Liechtenstein readers, the big health angle is EU approvals and regional access for new therapies and health-related tech.

Travel health access: UK travellers are being urged to get a GHIC before Europe trips, warning that without it you may have to pay local costs for state medical care. The card is free, replaces the EHIC after Brexit, and doesn’t replace travel insurance (no private care, repatriation, or disruption costs). Cancer care in Europe: The EU has approved Bristol Myers Squibb’s Opdivo (nivolumab) plus AVD as the first immunotherapy-based regimen for newly diagnosed advanced classical Hodgkin lymphoma in adults and adolescents (12+). CLL treatment update: AbbVie says the EU expanded VENCLYXTO (venetoclax) labeling to include fixed-duration combinations with acalabrutinib (± obinutuzumab) and with ibrutinib for first-line CLL, covering EU plus Iceland, Norway, and Liechtenstein. Transplant milestone: Hansa Biopharma reports strong one-year outcomes for Idefrix (imlifidase) after HLA-incompatible kidney transplants, with 90% graft failure-free survival in a European post-approval study. Heat and safety: A deadly spring heat wave across Europe has shattered temperature records and is linked to multiple deaths, including in the UK. Local relevance (Liechtenstein): Fi’s AI GPS pet wearable network now covers Switzerland, Norway, Liechtenstein, Iceland and more countries, expanding health insights for pets on the move.

New Cancer Treatment in Europe: The European Commission approved Bristol Myers Squibb’s Opdivo (nivolumab) plus AVD for adults and adolescents (12+) with previously untreated advanced classical Hodgkin lymphoma, marking the first immunotherapy-based regimen for newly diagnosed advanced cases in the EU. CLL Therapy Update: AbbVie received an expanded EU label for VENCLYXTO (venetoclax), adding fixed-duration combinations with acalabrutinib (with/without obinutuzumab) and with ibrutinib for previously untreated chronic lymphocytic leukemia—covering EU plus Iceland, Norway, and Liechtenstein. Transplant Milestone: Hansa Biopharma reported strong one-year outcomes for Idefirix (imlifidase) in highly sensitised patients after HLA-incompatible kidney transplants, with 90% graft failure-free survival at one year and 98% patient survival. Heat & Health Risk: A deadly spring heat wave across Europe shattered temperature records and has already been linked to multiple deaths, underscoring urgent heat-safety needs. Pet Health Tech in the Region: Fi expanded AI-powered GPS pet wearables to 38 countries, including Switzerland, Norway, and Liechtenstein, offering owners health insights and tracking while traveling.

Cancer Care in Europe: The European Commission approved Bristol Myers Squibb’s Opdivo (nivolumab) plus AVD for newly diagnosed advanced classical Hodgkin lymphoma in adults and adolescents (12+), marking the first immunotherapy-based regimen of its kind in the EU. CLL Treatment Update: AbbVie received an expanded EC label for VENCLYXTO (venetoclax), adding fixed-duration combinations with acalabrutinib (± obinutuzumab) and with ibrutinib for previously untreated chronic lymphocytic leukemia, with coverage across EU plus Iceland, Norway, and Liechtenstein. Transplant Medicine: Hansa Biopharma reported strong one-year outcomes for Idefrix (imlifidase) in highly sensitised kidney transplant patients, with 90% graft failure-free survival in a European post-approval study. Health & Travel Rules: UK authorities reminded travellers that bringing meat or dairy from the EU can trigger seizure and penalties up to £5,000, with rules aimed at preventing serious animal disease outbreaks. Disability Benefit Travel: The UK DWP confirmed strict holiday reporting rules for PIP claimants—long trips (over four weeks) and other life changes must be declared or payments can be affected. Pet Health Tech in Liechtenstein: Fi expanded AI GPS pet wearables to 38 countries, including connectivity for Switzerland, Norway, Liechtenstein, and more, targeting owners who want health insights while travelling.

Space & Health Research: Nevis and partners including the University of Zurich and the Centre for Space and Aviation Switzerland and Liechtenstein launched the first Caribbean space life sciences experiment (May 31) to study how microgravity and hypergravity affect human immune cells and gene activity—aimed at improving health knowledge for long-duration missions. Pet Health Tech in the Region: Fi expanded its AI-powered GPS pet wearables and connectivity network to 38 countries, adding several European markets and extending coverage to Switzerland, Norway, Liechtenstein, Iceland and Turkey—positioning the devices as tools for tracking health-related behavior trends. Cancer Care Update (EU): The European Commission authorized expanded use of Bristol Myers Squibb’s Opdivo (nivolumab) plus AVD for newly diagnosed advanced classical Hodgkin lymphoma in adults and adolescents (12+), marking a first immunotherapy-based regimen in the EU for this setting. Transplant Outcomes: Hansa Biopharma reported strong one-year results for Idefrix (imlifidase) after HLA-incompatible kidney transplants, with 90% graft failure-free survival in a European post-authorization study. Heat & Safety: A deadly spring heat wave across Europe shattered temperature records and has already been linked to multiple deaths, raising urgent public-safety concerns during extreme temperatures.

Pet health tech in the spotlight: Fi says its AI-powered GPS pet wearables are now available in 29 markets and work across Switzerland, Norway, Liechtenstein, Iceland and Turkey, expanding coverage to 38 countries—aimed at giving owners health insights and reliable tracking while traveling. Cancer care update: The EU has expanded approval for Bristol Myers Squibb’s Opdivo (nivolumab) plus AVD, positioning it as the first immunotherapy-based regimen in the EU for newly diagnosed advanced classical Hodgkin lymphoma in adults and adolescents (12+). CLL treatment options widen: AbbVie reports an expanded EU label for VENCLYXTO (venetoclax) to include additional fixed-duration combinations for previously untreated chronic lymphocytic leukemia, with authorization also covering Iceland, Norway and Liechtenstein. Transplant outcomes: Hansa Biopharma says its Idefrix (imlifidase) study in highly sensitised kidney transplant patients reached 90% one-year graft failure-free survival and 98% patient survival, supporting further approval steps. Heat and health risk: A deadly spring heat wave across Europe has shattered temperature records and is linked to multiple deaths, underscoring the need for cooling and safety planning. Disability benefit travel rules: The UK’s DWP confirms strict holiday reporting rules for PIP claimants—especially for trips longer than four weeks—to avoid fines or payment stops.

Tariff Relief for Health-Linked Industries: The U.S. eased parts of its steel, aluminium and copper tariffs, cutting duties on agricultural equipment (25% to 15%) and expanding a 15% category for industrial machinery—an update that could ease cost pressure for farmers, construction and housing supply chains. Cancer Care in Europe: Bristol Myers Squibb says the European Commission approved Opdivo (nivolumab) plus AVD for newly diagnosed advanced classical Hodgkin lymphoma in adults and adolescents (12+), marking a first immunotherapy-based frontline option in the EU. CLL Treatment Label Expanded: AbbVie reports the EC authorized expanded VENCLYXTO (venetoclax) combinations for previously untreated chronic lymphocytic leukemia, including with acalabrutinib (with/without obinutuzumab) and with ibrutinib—covering EU plus Iceland, Norway and Liechtenstein. Transplant Outcomes: Hansa Biopharma says Idefrix (imlifidase) showed 90% one-year graft failure-free survival in a European post-authorization study in highly sensitised kidney transplant patients, supporting strong longer-term results. Heat and Health Risk: A Europe-wide spring heat wave has shattered temperature records and is linked to deaths, with warnings that more harm is likely without protective action. Disability Benefit Holiday Rules: The UK DWP confirmed strict Personal Independence Payment (PIP) holiday rules for trips over four weeks, with possible fines or payment stops if claimants don’t report changes.

Cancer Care in Europe: Bristol Myers Squibb says the EU has expanded Opdivo (nivolumab) to a first immunotherapy-based frontline option for adults and adolescents (12+) with advanced classical Hodgkin lymphoma, using Opdivo plus AVD. CLL Treatment Update: AbbVie reports the European Commission authorized expanded VENCLYXTO (venetoclax) labeling for additional fixed-duration combinations in previously untreated chronic lymphocytic leukemia, including with acalabrutinib (± obinutuzumab) and with ibrutinib. Transplant Breakthrough: Hansa Biopharma says its Idefrix (imlifidase) study in highly sensitized kidney transplant patients reached strong one-year graft failure-free survival and patient survival results, supporting full approval progress. Bladder Cancer Pathway: The European Medicines Agency process backs pembrolizumab plus enfortumab vedotin as neoadjuvant then adjuvant treatment after surgery for certain cisplatin-ineligible muscle-invasive bladder cancer patients. Heat & Health Risk: A deadly spring heat wave across Europe has shattered temperature records and is linked to multiple deaths, underscoring the need for heat-safety planning. Travel Rules for Health: UK guidance warns travellers not to bring meat or dairy from the EU, with potential fines up to £5,000 for undeclared banned items. Everyday Disability Support: The UK DWP reiterates strict Personal Independence Payment holiday rules for trips longer than four weeks, including reporting requirements that can affect payments. Liechtenstein Link in Trade: A Norway envoy highlights India’s recent visit outcomes, noting EFTA ties that include Liechtenstein.

Cancer Care in Europe: The European Commission approved Bristol Myers Squibb’s Opdivo (nivolumab) plus AVD for adults and adolescents (12+) with newly diagnosed advanced classical Hodgkin lymphoma—positioning it as the first immunotherapy-based regimen for this setting in the EU. CLL Treatment Update: AbbVie’s VENCLYXTO (venetoclax) got an expanded EU label for first-line chronic lymphocytic leukemia, adding fixed-duration combinations with acalabrutinib (± obinutuzumab) and with ibrutinib across EU states including Liechtenstein. Bladder Cancer Option for Cisplatin-Ineligible Patients: The EU CHMP issued a positive opinion for perioperative pembrolizumab plus enfortumab vedotin followed by adjuvant treatment after radical cystectomy for resectable muscle-invasive bladder cancer in adults who can’t have cisplatin chemotherapy. Transplant Breakthrough: Hansa Biopharma reported strong one-year outcomes for Idefrix (imlifidase) in highly sensitised kidney transplant patients, with 90% graft failure-free survival at one year. Heat & Health Risk: A deadly spring heat wave across Europe has shattered temperature records and is linked to multiple deaths, underscoring the need for cooling and hydration. Disability Benefit Holiday Rules: The UK DWP confirmed strict Personal Independence Payment holiday rules for trips over four weeks, with potential fines or payment stops if claimants don’t report changes.

Cancer Care Update: AbbVie says the European Commission has authorized an expanded label for VENCLYXTO (venetoclax) in previously untreated chronic lymphocytic leukemia, including new fixed-duration combinations with acalabrutinib (with/without obinutuzumab) and with ibrutinib—covering EU states plus Iceland, Norway and Liechtenstein. Transplant Medicine: Hansa Biopharma reports strong one-year results for Idefrix (imlifidase) in highly sensitised kidney transplant patients, with 90% graft failure-free survival and 98% patient survival at one year, supporting further regulatory progress. Bladder Cancer Trial Progress: The EU’s CHMP has issued a positive opinion for perioperative pembrolizumab plus enfortumab vedotin for cisplatin-ineligible resectable muscle-invasive bladder cancer, with a final EU decision expected in Q3 2026. Public Health & Safety: A deadly spring heat wave across Europe has shattered temperature records and is linked to at least 18 deaths, with more expected. Travel Rules (Health-adjacent): UK authorities warn travellers not to bring meat or dairy from the EU, with fines up to £5,000 and possible prosecution for undeclared items. STEM & Health Education: A Caribbean–Swiss space biology mission launched from Sweden, including a partnership involving Liechtenstein’s CSA, aiming to boost STEM education and research capacity.

Cancer Care Update: The European Commission has authorized an expanded label for AbbVie’s VENCLYXTO (venetoclax) in previously untreated chronic lymphocytic leukemia, adding fixed-duration combinations with acalabrutinib (±obinutuzumab) and with ibrutinib—covering EU states plus Iceland, Norway, and Liechtenstein. Transplant Breakthrough: Hansa Biopharma reports 90% one-year graft failure-free survival in a European study of Idefrix (imlifidase) for highly sensitized kidney transplant patients, with patient survival at 98%. Health & Travel Rules: UK authorities warn PIP claimants about strict holiday reporting rules for trips over four weeks, with possible fines or payment stops. Public Health & Weather: A deadly spring heat wave across Europe has shattered temperature records and is linked to multiple deaths, including in the UK. STEM & Health Education: A Caribbean–Swiss space biology mission launched from Sweden, involving a partnership that includes Liechtenstein’s CSA, aiming to boost STEM learning and research capacity. Trade & Health Context: India and Oman’s CEPA takes effect June 1, expanding duty-free market access and services—an indirect factor that can shape health-sector supply and workforce mobility.

Space & STEM: A new Caribbean–Swiss space biology mission launched from Sweden, with a St. Kitts and Nevis–University of Zurich–CSA (including Liechtenstein) partnership aimed at boosting STEM education and research capacity. Cancer Care Update: AbbVie says the European Commission authorized an expanded VENCLYXTO® (venetoclax) label for previously untreated chronic lymphocytic leukemia, adding fixed-duration combinations with acalabrutinib (± obinutuzumab) and with ibrutinib—covering EU states plus Iceland, Norway, and Liechtenstein. Transplant Medicine: Hansa Biopharma reports strong one-year kidney transplant outcomes for Idefrix (imlifidase) in highly sensitized patients, with 90% graft failure-free survival in a European post-authorization study. Health Policy (Disability Benefits): The UK DWP reiterates strict Personal Independence Payment holiday rules for trips over four weeks, warning that failing to report changes can mean fines or payment stops. Climate & Health Risk: A Europe spring heat wave has shattered temperature records and is linked to multiple deaths, raising urgent public-health concerns. Trade & Health Context: India and Oman’s CEPA takes effect June 1, expanding duty-free access and services—part of a wider shift in regional economic ties that can affect healthcare supply chains and access.

Heat & Safety: Europe’s deadly spring heat wave has shattered temperature records, with at least 18 deaths reported in the U.K. and more feared as extreme heat persists. Cancer Care (Liechtenstein included): AbbVie says the European Commission authorized expanded use of VENCLYXTO (venetoclax) for previously untreated chronic lymphocytic leukemia, including new fixed-duration combinations that may offer treatment-free intervals. Bladder Cancer (Europe-wide): The EU CHMP issued a positive opinion for perioperative pembrolizumab plus enfortumab vedotin for certain cisplatin-ineligible muscle-invasive bladder cancer patients, with a final EC decision expected in Q3 2026. Transplant Outcomes: Hansa Biopharma reports strong one-year results for Idefrix (imlifidase) in highly sensitised kidney transplant patients, including 90% graft failure-free survival. Immunodeficiency Treatment: Pharming received EU marketing authorization for Joenja (leniolisib) for activated PI3K delta syndrome, with availability planned across EU countries including Liechtenstein. Travel Health/Rules: UK authorities warn travellers not to bring meat or dairy from the EU, with fines up to £5,000 and possible prosecution for undeclared items.